Capital Markets Trading (UK)’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-5,518
Closed -$353K 216
2021
Q4
$401K Sell
5,518
-16,620
-75% -$1.14M 0.01% 176
2021
Q3
$1.57M Sell
22,138
-55,036
-71% -$3.87M 0.02% 164
2021
Q2
$5.31M Buy
77,174
+27,352
+55% +$1.83M 0.09% 107
2021
Q1
$3.22M Buy
49,822
+3,274
+7% +$211K 0.05% 123
2020
Q4
$2.71M Buy
46,548
+5,557
+14% +$335K 0.03% 129
2020
Q3
$2.48M Buy
40,991
+31,894
+351% +$2.21M 0.04% 128
2020
Q2
$700K Buy
+9,097
New +$697K 0.02% 156
2020
Q1
Sell
-84,393
Closed -$5.48M 237
2019
Q4
$5.48M Buy
84,393
+48,821
+137% +$3.18M 0.21% 86
2019
Q3
$2.25M Buy
35,572
+13,427
+61% +$878K 0.1% 126
2019
Q2
$1.5M Buy
22,145
+5,783
+35% +$380K 0.07% 146
2019
Q1
$1.06M Sell
16,362
-74,103
-82% -$4.93M 0.06% 136
2018
Q4
$5.66M Buy
90,465
+14,400
+19% +$1.01M 0.32% 91
2018
Q3
$5.87M Sell
76,065
-37,641
-33% -$2.84M 0.29% 99
2018
Q2
$8.05M Buy
113,706
+65,763
+137% +$4.64M 0.39% 79
2018
Q1
$3.61M Buy
47,943
+43,114
+893% +$3.43M 0.17% 106
2017
Q4
$346K Buy
+4,829
New +$367K 0.01% 149

Other funds holding GILD

Capital Markets Trading (UK)'s GILD Position: Q1 2022 in Review

Capital Markets Trading (UK) sold out of Gilead Sciences (GILD) in Q1 2022, closing a stake of 5,518 shares — an estimated $353K sold.

Capital Markets Trading (UK) first reported a position in GILD in Q4 2017 and held it in 16 quarters. The position peaked at $8.05M in Q2 2018. 1,600 funds tracked by Wall St. Rank hold GILD as of Q1 2022.

  • Capital Markets Trading (UK) reported no remaining Gilead Sciences position as of Q1 2022 after selling out during the quarter.
  • Capital Markets Trading (UK) sold 5,518 Gilead Sciences shares in Q1 2022, an estimated $353K.
  • Capital Markets Trading (UK) first reported a position in Gilead Sciences in Q4 2017 and held it in 16 quarters.
  • Capital Markets Trading (UK)'s Gilead Sciences position peaked at $8.05M in Q2 2018.
  • 1,600 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2022.

Based on Capital Markets Trading (UK)'s 13F filing for Q1 2022, filed 16 May 2022.